Background
==========

Autoimmune diseases (ADs) are chronic conditions initiated by the loss of immunological tolerance to self-antigens; they represent a heterogeneous group of disorders that afflict specific target organs or multiple organ systems \[[@B1]\]. The chronic nature of these diseases places a significant burden on the utilization of medical care, increases direct and indirect economic costs, and diminishes quality of life. The estimated incidence of ADs is approximately 80 per 100,000 person years and their prevalence could be well beyond 3% of the population \[[@B2]\]. Most of the ADs asymmetrically affect middle-aged women and are among the leading causes of death for this group of patients. Although the frequency of ADs varies between countries \[[@B3]\], various studies have shown that, for some ADs, associations are found across populations \[[@B4]\].

ADs share several clinical signs and symptoms (that is, subphenotypes), physiopathological mechanisms, and genetic factors. These shared characteristics have been grouped under the term autoimmune tautology \[[@B5]-[@B10]\]. In clinical practice two conditions support this theory, namely, polyautoimmunity and familial autoimmunity, both of which are considered as being part of the \'kaleidoscope of autoimmunity\' \[[@B11]-[@B14]\]. Whereas polyautoimmunity is the presence of two or more ADs in a single patient, familial autoimmunity occurs when relatives from a nuclear family present diverse ADs \[[@B9]\] (Figure [1](#F1){ref-type="fig"}). These conditions indicate that similar genetic, epigenetic, and environmental factors influence the development of ADs \[[@B7]\]. The best examples of polyautoimmunity are the multiple autoimmune syndrome (MAS), which occurs when a patient has three or more ADs \[[@B15],[@B16]\], and the polyglandular autoimmune syndromes type II, III and IV \[[@B17]\], which are in fact MAS.

![**How do autoimmune diseases cluster in families? A)**Familial autoimmune disease. This classical concept indicates the same AD in diverse FDRs. In this case, a proband and a FDR (that is, the father) present with T1D. **B)**Familial autoimmunity. This new concept corresponds to the presence of different ADs in a nuclear family. **C)**Multiple autoimmune syndrome. This condition refers to the presence of three or more autoimmune diseases in the same subject. In this case, two brothers met criteria for the syndrome. Moreover, this pedigree also meets criteria for familial autoimmunity. **D)**Polyglandular autoimmune syndrome type II. In this family, however, familial autoimmune disease and familial autoimmunity coexist. The results of HLA genes (that is, A, B, DRB1, DQB1) typing are shown in colors (by reverse dot blot using InnoLipa Kit). A suggestive linkage among the HLA loci is observed. In these diagrams, people are represented by symbols: circles for female and squares for male, and the bottom line represents the offspring of the couple above. Solid symbols represent affected individuals. Symbol with a diagonal line indicates deceased individual. AdD, Addison\'s disease; AITD, autoimmune thyroid disease; APS, antiphospholipid syndrome; FDRs, first degree relative; MS, multiple sclerosis; PA, pernicious anemia; SLE, systemic lupus erythematosus; SS, Sjögren\'s syndrome; T1D, type 1 diabetes; VIT, vitiligo.](1741-7015-11-73-1){#F1}

ADs do not begin at the moment they become clinically apparent but several years before. This implies that there is a chance to predict autoimmunity. Over the years, several risk factors have been associated with the onset of ADs. Among these the most widely studied are female gender \[[@B18]\], specific alleles at HLA and non-HLA loci \[[@B2],[@B19]\] and some environmental agents \[[@B20],[@B21]\]. In addition, the presence of auto antibodies may also predict specific clinical manifestations, disease severity and disease progression \[[@B22]-[@B27]\]. As reviewed by Tobon *et al*. \[[@B5]\] many auto antibodies have a predictive ability and they can be serologically evaluated long before the appearance of clinical disease. Thus, identification of these markers as well as a family history of autoimmunity and evaluation of their predictive value could be useful for personalized medicine.

A primary characteristic of complex diseases is that they are likely to aggregate in families (that is, familial aggregation, also referred to as recurrence risk or lambda, λ). The aggregation of a phenotype is observed when a disease occurs at a higher frequency in the relatives of an affected individual as compared with the frequency observed in the general population. Values of λ \>1.0 indicate aggregation \[[@B9]\]. Aggregation of the same autoimmune condition, also referred to as familial autoimmune disease, has been extensively evaluated. However, aggregation of diverse autoimmune diseases, also known as familial autoimmunity, has been overlooked (Figure [1](#F1){ref-type="fig"}). Therefore, a systematic review and meta-analysis were performed aimed at gathering evidence about this topic.

Methods
=======

Systematic review
-----------------

A literature search was done even though \'familial autoimmunity\' is not a Medical Subject Headings (MeSH) term. Nevertheless, the search was done in the electronic databases Medline and Embase, and included articles, from 1966 for the former and 1980 for the latter, up to June 2012. The search strategy was limited to humans and included the words \'(familial OR clustering OR aggregation)\' AND \'autoimmunity followed by each of the diseases we have focused on: \'multiple sclerosis,\' \'diabetes mellitus, Type 1,\' \'arthritis, rheumatoid\' and \'lupus erythematosus, systemic\' using MeSH terms and key words for \'autoimmune thyroid disease\'. In order not to miss potentially eligible studies we used wild cards for the words familial, clustering and aggregation in the following manner: famil\*, aggrega\* and cluster\*. No language restrictions were used. Articles were included if they fulfilled the following conditions: ADs diagnosis was carried out according to international criteria or through international classification of diseases, articles were published as full articles and, as mentioned earlier, if ADs in first degree relatives (FDRs) were different than in the proband. Studies were excluded if they only referred to autoantibody prevalence, if a clear cut distinction between diseases was not possible, if it was not possible to distinguish between probands and FDRs, if the studies were case reports, and if they dealt with a single family. Unpublished data were also excluded. Eligibility assessment was done by a primary reviewer who screened all titles and abstracts of publications. Retrieved articles were rejected if eligibility criteria were not met and a secondary reviewer was consulted in cases in which eligibility criteria were unclear. References from the articles that seemed to be relevant for our review were hand-searched. All articles were assessed according to the Oxford Centre for Evidence-based Medicine 2011 Levels of Evidence \[[@B28]\]. The search returned articles in which familial autoimmunity was assessed in other ADs and they were included. From each study we extracted data including total number of FDRs, numbers of FDRs affected, prevalence of ADs and, where possible, extraction of crude and adjusted measures of association, that is, odds ratio (OR) or risk ratio (RR). With the prevalences extracted, aggregation for different ADs across the five index diseases mentioned earlier was calculated by dividing the prevalence of a given AD in FDRs by the prevalence in the general population (λ~relatives~). We extracted data on prevalences from five reports \[[@B2],[@B29]-[@B32]\]. Inclusion criteria for the meta-analyses were applied to publications that provided epidemiological data on risk factors, RR and OR with confidence intervals (CI), or that provided information that allowed us to calculate these data. If the study did not report the number of subjects in each group, either the RR or the OR with the CI, must have been reported in order for them to be included in the meta-analyses calculations.

In order to study aggregation, we determined worldwide prevalences of ADs from five studies mentioned earlier \[[@B2],[@B29]-[@B32]\]. If a range was reported, we arbitrarily calculated the mean.

Meta-analyses
-------------

Data were analyzed using the Comprehensive Meta-Analysis Version 2 program (Biostat, Englewood, NJ, 2004). Calculations were carried out for the whole group of articles depending on the binary data available for any AD: number of subjects and risk data (OR and RR with the corresponding 95% CI). Effect size was calculated based on studies that reported an OR with its respective 95% CI and from raw data given by case-control and cohort studies. If raw data from cohort studies were available, a second effect size was calculated with studies that only showed the RR and the respective 95% CI. Different study designs were used to compute the same effect size since the effect size had the same meaning in all studies and was comparable in relevant aspects. In order to perform the analyses, the association measures were transformed to log values, and then the results were converted back to ratio values for presentation. This approach prevented the omission of studies that used an alternative measure. Two types of meta-analyses were done in order to analyze autoimmunity as a trait. First, a given AD in FDRs was analyzed through all the studies regardless of the AD of the proband. The second type of meta-analysis analyzed ADs in FDRs through all the studies from a specific AD present in the proband.

Additional meta-analyses were done for studies with complex data structures and non-cumulative results as the information for the different effects was not totally independent. This is the case for studies reporting multiple independent subgroups, that is, aggregation for son and daughter separately, within a study. A flow diagram of the current study is shown in Figure [2](#F2){ref-type="fig"}.

![**Flow diagram of current study**. AITD, autoimmune thyroid disease; MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; T1D, type 1 diabetes.](1741-7015-11-73-2){#F2}

ORs were grouped by weighing individual ORs by the inverse of their variance. For each analysis, the final effect OR and 95% CI were obtained by means of the random effect model, which was preferred because it accepts distributions of true effect sizes rather than one true effect and assigns a more balanced weight to each study. It was also used because all the studies were considered to be unequal in terms of specific ADs.

Heterogeneity was calculated by means of Higgins\'s (*I^2^*) tests. The variance between studies was estimated by the DerSimonian and Laird method. The *I^2^*test showed the proportion of observed dispersion that was real rather than spurious and was expressed as a ratio ranging from 0% to 100%. *I^2^*values of 25%, 50%, and 75% were qualitatively classified as low, moderate, and high, respectively. Publication bias was determined using Funnel plots and Egger\'s regression asymmetry tests.

Results
=======

Studies retrieved
-----------------

After discarding duplicates, the search in both databases retrieved 2,552 articles. In a first assessment we considered 61 articles to be eligible. In a second screening 17 of these articles were not eligible due to reporting inconsistencies, such as not distinguishing between probands and FDRs. As we did not identify other articles from the reference lists, only 44 articles met eligibility criteria \[[@B32]-[@B75]\]. Figure [3](#F3){ref-type="fig"} and Table [1](#T1){ref-type="table"} summarize the search results. Although ankylosing spondylitis (AS) is considered an auto-inflammatory more than autoimmune disease \[[@B76]\], it was included in the results since it was found to aggregate in families. Most of the studies found lacked controls and had a small sample size, which is reflected in low grading according to the 2011 levels of evidence from the Oxford Centre for Evidence-based Medicine \[[@B28]\]. Detailed information is shown in Table [2](#T2){ref-type="table"}.

![**Flowchart summarizing the search results**.](1741-7015-11-73-3){#F3}

###### 

Significant associations of autoimmune diseases in first degree relatives.

  Proband´s disease                  Author                     Disease in first degree relatives                               References
  ---------------------------------- -------------------------- --------------------------------------------------------------- ------------
  Autoimmune thyroid disease         Boelaert *et al*.          AdD, CD, IBD, MG, MS, PA, RA, SLE, T1D, VIT                     \[[@B33]\]
                                     Hemminki *et al*.          In parent: AdD, IIM, MG, PA, RA, T1D, UC                        \[[@B34]\]
                                                                In sibling: Discoid lupus erythematosus, localized SSc, T1D     
                                                                In parent and sibling: SLE                                      
  Type 1 diabetes                    Bottazo *et al*.           AITD                                                            \[[@B36]\]
                                     Anaya *et al*.             AITD                                                            \[[@B37]\]
                                     Wagner *et al*.            AITD,CD, PSO, RA, VIT                                           \[[@B38]\]
                                     Hemminki *et al*.          In parent: AdD, AITD, AS, CD, PA, PBC, RA, SLE, UC, WG          \[[@B39]\]
                                                                In sibling: AdD, AITD, CD                                       
                                                                In parent and sibling: RA                                       
                                     Lebenthal *et al*.         AITD, CD                                                        \[[@B41]\]
  Systemic lupus erythematosus       Criswell *et al*.          AITD                                                            \[[@B35]\]
                                     Alarcon-Segovia *et al*.   AITD, IIM, RA, SSc                                              \[[@B42]\]
                                     Priori *et al*.            AITD, RA, T1D, VIT                                              \[[@B43]\]
                                     Corporaal *et al*.         MS, RA                                                          \[[@B44]\]
  Rheumatoid arthritis               Lin *et al*.               AITD, T1D,                                                      \[[@B45]\]
                                     Thomas *et al*.            T1D                                                             \[[@B46]\]
                                     Hemminki *et al*.          In parent: AITD, AS, Localized SSc, PA, PSO, SLE, SS, SSc, WG   \[[@B47]\]
                                                                In sibling: PSO, SLE                                            
                                     Jawaheer *et al*.          AITD                                                            \[[@B48]\]
  Multiple sclerosis                 Barcellos *et al*.         AITD, PSO, RA, T1D                                              \[[@B32]\]
                                     Criswell *et al*.          PSO                                                             \[[@B35]\]
                                     Broadley *et al*.          AITD                                                            \[[@B49]\]
                                     Deretzi *et al*.           AITD, IBD, PSO, T1D                                             \[[@B50]\]
                                     Heinzlef *et al*.          AITD, RA, T1D, VIT                                              \[[@B51]\]
                                     Henderson *et al*.         AS                                                              \[[@B52]\]
                                     Marrosu *et al*.           T1D                                                             \[[@B53]\]
                                     Nielsen *et al*.           AdD, CrD, PAN,                                                  \[[@B55]\]
  Systemic sclerosis                 Arora-Singh *et al*.       AITD, RA, SLE,                                                  \[[@B57]\]
                                     Hudson *et al*.            AITD, PBC, RA, SLE, SS                                          \[[@B58]\]
                                     Koumakis *et al*.          AITD, RA, SLE, SS                                               \[[@B59]\]
  Sjögren\'s syndrome                Reveille *et al*.          AITD, MS, SLE, SSc                                              \[[@B61]\]
                                     Anaya *et al*.             AITD, RA, SLE                                                   \[[@B62]\]
  Inflammatory bowel disease         Criswell *et al*.          MS                                                              \[[@B35]\]
  Ulcerative colitis                 Hemminki *et al*.          In parent: AITD, AS, CrD, MS, PA, PAN, PSO, RA, SLE, T1D        \[[@B63]\]
                                                                In sibling: AS, CrD                                             
                                                                In parent and sibling: CrD, PSO                                 
  Crohn\'s disease                   Hemminki et al.            In parent: AS, PSO, UC                                          \[[@B63]\]
                                                                In sibling: AS, UC                                              
                                                                In parent and sibling: RA, UC                                   
                                                                In twins: UC                                                    
  Vitiligo                           Alkhateeb *et al*.         AdD, AITD, MG, PA, SLE, SSc                                     \[[@B64]\]
                                     Laberge *et al*.           AdD, AITD, PA, PSO, RA                                          \[[@B65]\]
                                     Zhang *et al*.             AA, PSO, RA                                                     \[[@B66]\]
  Juvenile rheumatoid arthritis      Prahalad *et al*.          AITD                                                            \[[@B67]\]
                                     Huang *et al*.             AITD, AS, PSO, SLE                                              \[[@B68]\]
  Juvenile lupus erythematosus       Huang *et al*.             AITD, AS, MG                                                    \[[@B68]\]
  Inflammatory idiopathic myositis   Ginn *et al*.              AITD, PA, PSO, RA, SS, T1D                                      \[[@B70]\]
  Celiac disease                     Petaros *et al*.           AITD, PSO, T1D                                                  \[[@B72]\]
                                     Cataldo *et al*.           AITD, T1D                                                       \[[@B73]\]
                                     Neuhausen *et al*.         JRA, T1D                                                        \[[@B74]\]
  Alopecia areata                    Kakourou *et al*.          AITD, CD, PSO, T1D, VIT                                         \[[@B75]\]

AA, alopecia areata; AdD, Addison\'s disease; AS, ankylosing spondylitis; AITD, autoimmune thyroid disease; CD, celiac disease; CrD, Crohn\'s disease; IBD, inflammatory bowel disease; IIM, idiopathic inflammatory myositis; JDM, juvenile dermatomyositis; JRA, juvenile rheumatoid arthritis; JSLE, juvenile systemic lupus erythematosus; MAS, multiple autoimmune syndrome; MG, myasthenia gravis; MS, multiple sclerosis; PA, pernicious anemia; PAN, polyarteritis nodosa; PBC, primary biliary cirrhosis; PSO, psoriasis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjögren\'s syndrome; SSc, systemic sclerosis; T1D, type 1 diabetes; UC, ulcerative colitis; VIT, vitiligo; WG, Wegener\'s granulomatosis. Note: Although AS is considered an auto-inflammatory more than autoimmune disease \[[@B76]\] we show the results obtained.

###### 

Characteristics of the studies included.

  Disease in probands   Author and year                   Country            Study type        Total number of probands   Affected FDRs in probands   Total number FDRs   Total controls   Affected FDRs in controls   Total FDRs in controls   Oxford 2011 level of evidence   Observations
  --------------------- --------------------------------- ------------------ ----------------- -------------------------- --------------------------- ------------------- ---------------- --------------------------- ------------------------ ------------------------------- --------------------------------------------------------------------------------------------------
  AITD                                                                                                                                                                                                                                                                          
                        Boelaert 2010 \[[@B33]\]          UK                 Cross sectional   3286                       845                         6572                                                                                      3                               
                        Hemminki 2009 \[[@B34]\]          Sweden             Cohort            15,743                     1,135                       2,412                                                                                     3                               
                        Criswell 2005 \[[@B35]\]          USA                Cross sectional   43                         21                          232                                                                                       3                               
  T1D                                                                                                                                                                                                                                                                           
                        Criswell 2005 \[[@B35]\]          USA                Cross sectional   10                         6                           232                                                                                       3                               
                        Bottazzo 1978 \[[@B36]\]          UK                 Cross sectional   116                        4                           257                                                                                       3                               
                        Anaya 2006 \[[@B37]\]             Colombia           C&C               98                         18                          312                 113              9                           362                      3                               
                        Wagner 2011 \[[@B38]\]            Spain              Cross sectional   12,973                     97                          1,279                                                                                     3                               Non diabetic siblings
                                                                                               12,973                     1,001                       6,262                                                                                                                     Diabetic siblings
                        Hemminki 2009 \[[@B39]\]          Sweden             Cohort            21,168                     1,913                       5,195                                                                                     3                               
                        Samuelsson 2004 \[[@B40]\]        Lithuania/Sweden   C&C               803                        114                                             1,944            229                                                  3                               N = for controls and for FDRs is not specified
                        Lebenthal 2011^a^\[[@B41]\]       Israel             Cross sectional   121                        57                                                                                                                    3                               Familial T1D patients
                                                                                               226                        43                                                                                                                                                    Sporadic T1D patients.
                                                                                                                                                                                                                                                                                Numbers of FDRs are not given
  SLE                                                                                                                                                                                                                                                                           
                        Alarcón Segovia 2005 \[[@B42]\]   Latin america      Cross sectional   1,177                      50                                                                                                                    3                               Total number of FDRs is not specified
                        Priori 2003 \[[@B43]\]            Italy              C&C               154                        39                          759                 140              12                          776                      3                               
                        Corporaal 2002 \[[@B44]\]         The Netherlands    Cross sectional   135                        42                          693                                                                                       3                               
                        Criswell 2005 \[[@B35]\]          USA                Cross sectional   65                         47                          232                                                                                       3                               
  RA                                                                                                                                                                                                                                                                            
                        Criswell 2005 \[[@B35]\]          USA                Cross sectional   46                         31                          232                                                                                       3                               
                        Lin 1998 \[[@B45]\]               USA                C&C               29                         25                          218                 14               4                           98                       3                               
                        Thomas 1983 \[[@B46]\]            UK                 C&C               295                        19                          2,081               307              8                           2,299                    3                               
                        Hemminki 2009 \[[@B47]\]          Sweden             Cohort            47,361                     1,919                       4,677                                                                                     3                               
                        Jawaheer 2004 \[[@B48]\]          USA                C&C               1,097                      10                                                               83                                                   3                               N = for controls and for total FDRs are not specified
  MS                                                                                                                                                                                                                                                                            
                        Barcellos 2006 \[[@B32]\]         USA                Cross sectional   176                        119                         1,107                                                                                     3                               
                        Criswell 2005 \[[@B35]\]          USA                Cross sectional   82                         64                          232                                                                                       3                               
                        Broadley 2000 \[[@B49]\]          UK                 C&C               571                        879                         3,949               375              879                         3949                     3                               Individual numbers of FDRs of cases and controls are not given
                        Deretzi 2010 \[[@B50]\]           Greece             C&C               891                        410                         3,112               355              96                          1580                     3                               
                        Heinzlef 2000 \[[@B51]\]          France             Cross sectional   357                        33                          1,971                                                                                     4                               
                        Henderson 2000 \[[@B52]\]         Australia          C&C               157                        53                          722                 222              1582                        1138                     3                               
                        Marrosu 2002 \[[@B53]\]           Italy              Cohort            1,090                      53                          5,480                                                                                     3                               
                        Ramagopalan 2007 \[[@B54]\]       Canada             Cross sectional   5,031                      786                         30,259                                                                                    3                               
                        Nielsen 2008 \[[@B55]\]           Denmark            Cohort            8,205                      260                         20,800                                                                                    3                               
                        Laroni 2005 \[[@B56]\]            Italy              C&C               245                        21                          984                 245              13                          1,002                    4                               
  SSc                                                                                                                                                                                                                                                                           
                        Arora Singh 2010 \[[@B57]\]       USA                                  1,071                      184                         4,612                                                                                     3                               
                        Hudson 2008 \[[@B58]\]            Canada             Cross sectional   719                        260                         715                                                                                       3                               
                        Koumakis 2012 \[[@B59]\]          France             C&C               373                        245                         823                 250              70                          318                      3                               
                        Frech 2010 \[[@B60]\]             USA                Nested C&C        1,037                      95                          4,629               10,370           417                         49,312                   3                               Total number of FDRs, from controls, is not specified but ten controls were selected per proband
  SS                                                                                                                                                                                                                                                                            
                        Reveille 1984 \[[@B61]\]          USA                Cross sectional   98                                                                                                                                               3                               Total number of FDRs and affected FDRs are not specified
                        Anaya 2006 \[[@B62]\]             Colombia           C&C               101                        56                          876                 124              33                          857                      3                               
  UC                                                                                                                                                                                                                                                                            
                        Hemminki 2010 \[[@B63]\]          Sweden             Cohort            25,846                     2,528                       5,121                                                                                     3                               
  CrD                                                                                                                                                                                                                                                                           
                        Hemminki 2010 \[[@B63]\]          Sweden             Cohort            18,885                     2,169                       4,306                                                                                     3                               
  IBD                                                                                                                                                                                                                                                                           
                        Criswell 2005 \[[@B35]\]          USA                Cross sectional   7                          8                           232                                                                                       3                               
  VIT                                                                                                                                                                                                                                                                           
                        Alkhateeb 2003 \[[@B64]\]         USA/UK             Cross sectional   2,624                      660                         8,034                                                                                     3                               
                        Laberge 2005 \[[@B65]\]           USA                Cross sectional   133                        98                          331                                                                                       3                               
                        Zhang 2009 \[[@B66]\]             China              Cross sectional   5,601                      340                         18,705                                                                                    3                               
  JRA                                                                                                                                                                                                                                                                           
                        Prahalad 2002 \[[@B67]\]          USA                C&C               110                        72                          446                 45               29                          181                      3                               
                        Huang 2004 \[[@B68]\]             Taiwan             Cross sectional   110                        5                                                                                                                     3                               Total number of FDRs is not specified
  JSLE                                                                                                                                                                                                                                                                          
                        Huang 2004 \[[@B68]\]             Taiwan             Cross sectional   91                         6                                                                                                                     3                               Total number of FDRs is not specified
                        Walters 2012 \[[@B69]\]           USA                Cross sectional   69                         23                                                                                                                    3                               Total number of FDRs is not specified
  IIM                                                                                                                                                                                                                                                                           
                        Ginn 1998 \[[@B70]\]              USA                C&C               21                         33                          151                 21               7                           143                      3                               
                        Niewold 2011 \[[@B71]\]           USA                Cross sectional   304                        30                          1,224                                                                                     3                               
  CD                                                                                                                                                                                                                                                                            
                        Petaros 2002 \[[@B72]\]           Italy              C&C               125                        18                          373                 125              4                           352                      3                               
                        Cataldo 2003 \[[@B73]\]           Italy              C&C               66                         11                          225                 68               2                           232                      3                               
                        Neuhausen 2008 \[[@B74]\]         USA                Cross sectional   408                        58                          1,272                                                                                     3                               
  AA                                                                                                                                                                                                                                                                            
                        Kakouroru 2007 \[[@B75]\]         Greece             C&C               157                                                                        100                                                                   3                               Total number of FDRs and affected FDRs are not specified
  PSO                                                                                                                                                                                                                                                                           
                        Criswell 2005 \[[@B35]\]          USA                Cross sectional   8                          8                           232                                                                                       3                               

^a^Numbers depicted represent families and not family members. Note: Only classical ADs are taken into account. Although some studies did not report the number of FDRs they specified other measures of association. See text for more details. AA, alopecia areata; AITD, autoimmune thyroid disease; C&C, case control; CD, celiac disease; CrD, Crohn\'s disease; IBD, inflammatory bowel disease; IIM, idiopathic inflammatory myositis; JRA, juvenile rheumatoid arthritis; JSLE, juvenile systemic lupus erythematosus; MS, multiple sclerosis; PSO, psoriasis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjögren\'s syndrome; SSc, systemic sclerosis; T1D, type 1 diabetes; UC, ulcerative colitis; VIT, vitiligo.

Autoimmune thyroid disease
--------------------------

Three articles assessed familial autoimmunity for autoimmune thyroid disease (AITD) \[[@B33]-[@B35]\]. AITD encompasses Graves\' disease as well as Hashimoto\'s thyroiditis with the latter being the most common cause of acquired hypothyroidism \[[@B77]\]. Moreover, AITD is the most common AD \[[@B78]\]. Various studies have shown that AITD coexists with other ADs in the same subject \[[@B79],[@B80]\] and it has also been shown that there is familial clustering of AITD in FDRs, particularly in female relatives \[[@B81]\]. Boelaert *et al*. \[[@B33]\] described familial autoimmunity among probands with Hashimoto\'s thyroiditis or Graves\' disease. Both ADs were significantly associated with the presence of type 1 diabetes mellitus (T1D), rheumatoid arthritis (RA), pernicious anemia (PA), systemic lupus erythematosus (SLE), celiac disease (CD), vitiligo (VIT) and multiple sclerosis (MS). Only Graves\' disease was associated with Addison\'s disease (AdD) and inflammatory bowel disease (IBD). Compared with the general population, familial autoimmunity in Graves\' disease probands disclosed PA as the strongest association (RR: 14.1; 95% CI: 11.48 to 17.03), followed by RA (RR: 13.5; 95% CI: 12.32 to 14.86).

Hemminki *et al*. \[[@B34]\] assessed familial autoimmunity only in probands with Graves\' disease from Sweden. To calculate familial risk within a large community based cohort they calculated standardized incidence ratios (SIR) as the ratio between the observed and the expected frequency for each disease. A value over one indicates an increased frequency of what is expected whereas a value below one indicates a decreased frequency. The analysis was stratified according to the FDR involved. For a single parent affected, Hashimoto\'s disease, PA, and RA were the only diseases significantly associated, having a SIR of 2.04, 1.82 and 1.48, respectively, thus showing an increased frequency of what is expected. Significant associations for singleton siblings were found for T1D, discoid lupus and localized scleroderma, having a SIR of 2.14, 6.03 and 6.62, respectively. If a parent and a sibling were affected with the same AD, the significant association was between Hashimoto\'s disease with a SIR of 37.41 and SLE with a SIR of 14.33 \[[@B34]\].

Type 1 diabetes mellitus
------------------------

The search returned seven articles about T1D probands \[[@B35]-[@B41]\]. AITD was responsible for the familial autoimmunity found in most of the articles \[[@B36],[@B40]\], even when compared to control subjects \[[@B37]\]. Wagner *et al*. \[[@B38]\] replicated the results but also described the presence of CD, psoriasis (PSO), and VIT.

Hemminki *et al*. \[[@B39]\] also reported familial autoimmunity in probands with T1D. When a parent had AdD, the SIR for T1D in offspring was 2.41. It was 2.73 for CD, 1.83 for Graves\' disease, 2.13 for Hashimoto\'s thyroiditis, 3.09 for PA, 3.63 for primary biliary cirrhosis (PBC), 2.12 for RA, 1.62 for SLE, 1.23 for ulcerative colitis (UC), and 1.23 for Wegener\'s granulomatosis (WG). Only the presence of AdD, CD or Graves\' disease in singleton siblings was associated with T1D in probands. Likewise, when a parent and sibling had RA, the SIR for T1D was 5.34 \[[@B39]\].

Systemic lupus erythematosus
----------------------------

Four articles assessed familial autoimmunity in SLE probands. Alarcon-Segovia *et al*. evaluated familial aggregation in the \'Grupo Latinoamericano de Estudio de Lupus\' (GLADEL) \[[@B42]\]. They found that among all family members who had any AD, 6.7% had RA, 2% AITD and other ADs at a lesser frequency. In FDR (n = 114) with ADs, 28% (n = 32) had RA and 16% (n = 32) had AITD \[[@B42]\]. Likewise, an increased frequency of familial autoimmunity was found in SLE probands compared with population prevalence. Priori *et al*. \[[@B43]\] found an OR of 4.6 (95% CI 1.94 to 11.1) in a multivariate analysis of familial autoimmunity in FDR of SLE patients. They reported AITD as the most frequent disease with eight cases, followed by RA with five cases, VIT with three cases and T1D with two cases. PSO frequency was higher among non-autoimmune controls. Sjögren´s syndrome (SS) as well as AITD were described by Scofield *etal*. \[[@B82]\] while Corporaal *et al*. \[[@B44]\] found clustering of MS and RA.

Rheumatoid arthritis
--------------------

In RA, familial autoimmunity was ascertained in five articles, all of which linked AITD or T1D to AR. Lin *et al*. \[[@B45]\] showed an association with AITD in 7.8% of the probands and T1D in 2.8%. Thomas *et al*. \[[@B46]\] also reported T1D as the disease responsible for familial autoimmunity. In another study, Taneja *et al*. \[[@B83]\] stated that SLE, T1D, AITD, SS, PSO and systemic sclerosis (SSc) were found in families with RA. However, they included probands within this description, thus assessing and combining polyautoimmunity or MAS with familial autoimmunity. Walker *etal*. \[[@B84]\] found an excess risk for AITD in RA multicase families compared with the general population. However, this significance was lost when RA sufferers were withdrawn from the analysis. Jawaheer *et al*. \[[@B48]\] found the presence of AITD and other ADs in siblings but, compared with siblings of non-RA probands, the difference was not significant.

Hemminki *et al*. \[[@B47]\] also reported familial autoimmunity in probands with RA. Just as described above, when a parent had AS, the SIR for RA in offspring was 2.96. It was 2.25 for SS, 2.13 for SLE, 1.65 for SSc, 1.54 for AITD, 1.53 for PA, 1.36 for PSO and 1.34 for WG. When singleton siblings had PSO, the SIR for RA of the proband was 2.01 and 2.77 for SLE.

Multiple sclerosis
------------------

In our search, MS was the AD with the most articles assessing familial autoimmunity with 10 articles found \[[@B32],[@B35],[@B49]-[@B56]\]. Some studies suggest that FDRs and other relatives of probands with MS could be at greater risk of ADs other than MS \[[@B32],[@B35],[@B49]-[@B55],[@B57]\] while the studies done by Ramagopalan *et al*. \[[@B54]\] and Midgard *et al*. \[[@B85]\] do not support these findings. Although Annunziata *et al*. \[[@B86]\] found an association between MS and other ADs in first and second degree relatives, the results were not significant when compared to non-AD controls. Conversely, Alonso *et al*. \[[@B87]\] and Magaña *et al*. \[[@B88]\] found a significant association between MS and other ADs in relatives of any degree.

Using 265 families from the Multiple Autoimmune Disease Genetics Consortium (MADGC), Criswell *et al*. \[[@B35]\] compared the frequency of ADs in siblings of multiplex families stratified by seven ADs: AITD, RA, MS, SLE, T1D, IBD and PSO. These diseases were pre-specified given a variety of considerations. There was no evidence of familial autoimmunity except in the case of IBD patients in whose families MS was observed among FDRs (OR: 8.1; 95% CI: 1.77 to 37.0; *P*value = 0.018). However, selection bias was present as families selected for inclusion were not recruited in the same manner \[[@B35]\].

Meta-analyses
-------------

For the first effect size, OR, 13 meta-analyses were developed. Ten analyzed the proportion of a specific AD in FDRs independent of the AD present in the proband. Of these, three showed significant association: AITD, T1D and IBD. Three included an independent AD in FDRs in a specific AD of the proband, two of them showed significant associations: RA and MS. Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"} show the forest plots corresponding to six meta-analyses.

![**Forest plots depicting odds ratios for specific autoimmune diseases in first degree relatives**. Familial autoimmunity has to be seen as a two way relationship depending on which member of the nuclear family is the proband. Therefore, grouping meta-analysis by the disease present in FDRs is equivalent to analyzing it by the disease present in the proband. The figure shows four different analyses. From top to bottom autoimmune thyroid disease (**A**), type 1 diabetes mellitus (**B**), inflammatory bowel disease (**C**) and familial autoimmunity (**D**) assessed as an outcome. The summary effect (random effect model) is depicted as a diamond at the bottom of each analysis. The lateral points of each diamond indicate confidence intervals for this estimate. ^a^Numbers represent different subgroups within the study.](1741-7015-11-73-4){#F4}

![**Forest plots depicting odds ratios for familial autoimmunity**. The figure shows two different analyses. From top to bottom: (**A**) rheumatoid arthritis (RA), (**B**) multiple sclerosis (MS). Autoimmune diseases in first degree relatives through all the studies from a specific autoimmune disease present in the proband were analyzed. The summary effect (random effect model) is depicted as a diamond at the bottom of each analysis. The lateral points of each diamond indicate confidence intervals for this estimate. ^a^Numbers represent different subgroups within the study.](1741-7015-11-73-5){#F5}

A second effect size was calculated based on data from studies showing RR data. Twenty eight meta-analyses were developed. Twenty three analyzed the proportion of a specific AD in the FDR through all the studies independent of any AD of the proband. Of these, nineteen showed significant association, the most relevant results being related to VIT, PA, RA and T1D. Additional results are shown in Additional file [1](#S1){ref-type="supplementary-material"}. Through all the studies, four additional analyses performed included any AD present in FDRs. All these analysis disclosed significant results. The ADs in the proband were AITD, MS, RA and T1D (Figures [6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}).

![**Forest plots depicting risk ratios for familial autoimmunity in probands with AITD and MS**. The figure shows two different analyses. From top to bottom: autoimmune thyroid disease (**A**) and multiple sclerosis (**B**). The summary effect (random effect model) is depicted as a diamond at the bottom of each analysis. The lateral points of each diamond indicate confidence intervals for this estimate. ^a^Numbers in the study name represent different subgroups within the study. AITD, autoimmune thyroid disease; MS, multiple sclerosis.](1741-7015-11-73-6){#F6}

![**Forest plots depicting risk ratios for familial autoimmunity in probands with T1D and RA**. The figure shows two different analyses. From top to bottom: type 1 diabetes mellitus (**A**) and rheumatoid arthritis (**B**). The summary effect (random effect model) is depicted as a diamond at the bottom of each analysis, the lateral points of which indicate confidence intervals for this estimate. ^a^Numbers in the study name represent different subgroups within the study. RA, rheumatoid arthritis; T1D, type 1 diabetes.](1741-7015-11-73-7){#F7}

Evidence of significant publication bias was identified using the Egger test (*P*-value 2-tailed: \<0.05) for two meta-analyses which included studies that reported OR with its respective 95% CI (T1D in FDR (*P*-value 2-tailed: 0.047) and MS in probands (*P*-value 2-tailed: 0.007)). One meta-analysis that reported RR data showed publication bias by the Egger test (AITD in probands (*P*-value 2-tailed: 0.008)) (Figure [6A](#F6){ref-type="fig"}). The corresponding funnel plot showing the standard error or the precision on the Y axis is shown in Additional file [2](#S2){ref-type="supplementary-material"}. Therefore, a second analysis was run in a search for publication bias. The classic fail-safe analysis indicated a number of missing studies that would give a *P*-value of \>0.05. Begg and Mazumdar rank correlation was not significant and the trim and fill adjustment did not suggest a lower risk than the original analysis. Based on all the analyses for publication bias, we consider the impact of bias in the three meta-analyses to be trivial.

Familial autoimmunity as an outcome was also assessed in certain articles, particularly in MS and SLE probands (Figure [4D](#F4){ref-type="fig"}).

Aggregation
-----------

Several studies retrieved only reported prevalences of ADs in FDRs. Aggregation, based on data from five studies mentioned earlier in Table [3](#T3){ref-type="table"}\[[@B2],[@B29]-[@B32]\], is shown in Table [4](#T4){ref-type="table"}, which discloses information on calculated aggregation for diverse ADs, in AITD, T1D, SLE, RA and MS.

###### 

Prevalence of specific autoimmune diseases^a^

  Autoimmune disease                    Prevalence (%)
  ------------------------------------- ----------------
  Any autoimmune disease                3 to 8
  Addison\'s disease                    0.009
  Alopecia areata                       0.15
  Ankylosing spondylitis                0.20
  Autoimmune hepatitis                  ≤0.001
  Celiac disease                        0.75
  CREST syndrome                        ≤0.001
  Diabetes (type 1)                     0.190
  Graves\' disease                      1.200
  Hashimoto\'s thyroiditis              0.800
  Idiopathic thrombocytopenic purpura   ≤0.001
  Inflammatory bowel disease            0.450
  Juvenile idiopathic arthritis         0.148
  Multiple sclerosis                    0.058
  Myasthenia gravis                     0.005
  Pernicious anemia                     0.150
  Polymyositis/dermatomyositis          0.005
  Primary biliary cirrhosis             0.004
  Psoriasis                             0.75
  Rheumatoid arthritis                  1
  Sjögren\'s syndrome                   0.3
  Systemic lupus erythematosus          0.024
  Systemic sclerosis (scleroderma)      0.004
  Vitiligo                              0.4
  Wegener\'s granulomatosis             0.003

^a^Prevalences according to \[[@B2],[@B29]-[@B32]\]. CREST, Calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia.

###### 

Aggregation of ADs.

                       Disease in probands                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  -------------------- --------------------- ------------------ ------------------------ --------------------- ------------------------- ------------------ ------------------- ------------------- ----------------------------- ------------------ --------------------- --------------------- ------------------ --------------------- -------------------- --------------------- --------------------- ---------------------------------- -------------------------------- ------------------------- --------------------------------- ------------------------------- ----------------------
                       **T1D**               **AITD**           **SLE**                  **RA**                **MS**                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  **AD in FDRs**       **USA**\[[@B35]\]     **UK**\[[@B36]\]   **Colombia**\[[@B37]\]   **Spain**\[[@B38]\]   **Swed/Lith**\[[@B40]\]   **UK**\[[@B33]\]   **USA**\[[@B35]\]   **USA**\[[@B35]\]   **Latin America**\[[@B42]\]   **NL**\[[@B44]\]   **USA 1**\[[@B35]\]   **USA 2**\[[@B45]\]   **UK**\[[@B46]\]   **USA 3**\[[@B48]\]   **USA1**\[[@B32]\]   **USA 2**\[[@B35]\]   **USA 3**\[[@B87]\]   **Greece (Multiplex)**\[[@B50]\]   **Greece (Simplex)**\[[@B50]\]   **Australia**\[[@B52]\]   **Italy (Multiplex)**\[[@B53]\]   **Italy (Simplex)**\[[@B53]\]   **Canada**\[[@B54]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  AITD                 11.11                 0.98               2.4                      4.6                   0.88                                                             21.7                16                            20                 14.7                  3.9                   4.81               5.50                                       13,28                                                                                                                                                                                                       
  Hyperthyroidism^a^                                                                                                                     4.2                                                                                                                                                                                              3.75                                       22.1                  9.42                               8.2                              14.15                                                                                       
  Hypothyroidism ^a^                                                                                                                     7.38                                                                                                                                                                                                                                                              1.71                               0.74                             9.43                                                                                        
  T1D                                                           13.5                                                                     7.53               78.9                39.7                                              12.53              30.9                  14.49                                                                               74                    93.2                  14.41                              5.41                             49.65                     11.70                             3.51                            1.93
  RA                                                                                     0.9                                             7.41               22.5                16.98               64                            28.57                                                                                                   2.0                  7.8                   18.7                  0.68                               0.18                             20.75                                                                                       1.73
  PA                                                            2.14                                                                     12.38                                                                                                                                                                                                                                                                                                                                                                                                                             
  SLE                  462                                      13.35                                                                    5.71               312.5                                                                 595                163.4                                                                                                     390                   225                   42.8                               25                               471                                                                                         
  AdD                                                                                                                                    4.81                                                                                                                                                                                                                                                                                                                                                                                                                              
  CD                                                                                     3.6                   0.54                      0.39                                                                                                                                                                                                                                                                                                                                                                                                                              
  VIT                                                           0.8                      2.75                                            1.6                                                                                                                                                                                                                                                               0.86                               0.09                             4.72                                                                                        
  MS                                                                                                                                     7.61               86.2                130                                               164                67.6                                                                                                                                                                                                                                                                                                                  
  MG                                                                                                                                     9.13                                                                                                                              9.17                                                                                                                            68.49                              7.09                                                                                                                         
  IBD                                                                                    0.89                                            1.25               30                  4.2                                                                  21.79                                                                                4.44                 24                                          10.9                               7.38                             15.09                                                                                       
  PSO                  14.8                                                              1.6                                                                                    10                                                                   15.69                                                                                2.67                 25                                          5.48                               1.77                             33.9                                                                                        
  SS                                                                                                                                                                                                                              7.9                                                                                                                                                                      6.85                               1.77                                                                                                                         
  AS                                                                                                                                                                                                                                                                       2.29                                                                                                                                                                                                56.6                                                                                        
  SSc                                                                                                                                                                                               500                           595                                                                                                                                                                                                                                          471                                                                                         
  IIM                                                                                                                                                                                               400                                                                                                                                                                                                                                                                                                                                                                    

Table shows aggregation (λ) of ADs. The top row depicts the AD present in the proband while the first column shows the AD present in FDRs. The numbers correspond to the calculation of aggregation. ^a^Only autoimmune hypothyroidism and hyperthyroidism are depicted. Prevalences in the general population according to \[[@B2],[@B29]-[@B32]\]. If a range was reported the mean was calculated. AdD, Addison\'s disease; AS, ankylosing spondylitis; AITD, autoimmune thyroid disease; CD, celiac disease; IBD, inflammatory bowel disease; IIM, idiopathic inflammatory myositis; Lith, Lithuania; MG, myasthenia gravis; MS, multiple sclerosis; NL, The Netherlands; PA, pernicious anemia; PSO, psoriasis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjögren\'s syndrome; SSc, systemic sclerosis; Swed, Sweden; T1D, type 1 diabetes; VIT, vitiligo.

Other autoimmune diseases
-------------------------

The systematic search we performed retrieved other studies that assessed familial autoimmunity besides the five ADs we were focused on. These ADs are SSc, SS, IBD, juvenile dermatomyositis (JDM), VIT, juvenile rheumatoid arthritis (JRA), juvenile SLE (JSLE), idiopathic inflammatory myositis (IIM), CD, and alopecia areata (AA).

Systemic sclerosis
------------------

Four studies reported diagnosis of AITD, RA and SLE in FDRs of SSc probands \[[@B57]-[@B60]\]. Frech *et al*. \[[@B60]\] found a RR of 2.49 (95% C.I. 1.99 to 3.41) for familial autoimmunity in FDRs and a RR of 1.48 (95% C.I.1.34 to 2.39) for familial autoimmunity in second degree relatives.

Sjögren´s syndrome
------------------

Two studies were found on this disease, one by Reveille *et al*. \[[@B61]\] and the other done by our group \[[@B62]\]. Both studies agreed on the occurrence of AITD and SLE among relatives. In addition to these ADs, we described the presence of RA \[[@B62]\] while Reveille *et al*. \[[@B61]\] reported the occurrence of MS and SSc.

Inflammatory bowel disease
--------------------------

Two studies were retrieved. As mentioned earlier, Criswell *et al*. \[[@B35]\] found an increased frequency of familial autoimmunity among probands with IBD. A study conducted by Hemminki *et al*. \[[@B63]\] assessed familial autoimmunity within IBD probands. In UC patients when a parent had AS the SIR for UC in offspring was 1.6, for Crohn\'s disease (CrD) 2.5, for T1D 1.2, for Graves\' disease 1.3, for MS 1.4, for polyarteritis nodosa (PAN) 2.0, for PSO 1.3, for RA 1.1, and for SLE 1.5 \[[@B63]\]. When singleton siblings had CD, the SIR for UC was 2.5, and for AS was 2.1. When a parent and a sibling had CrD the SIR for UC was 4.7 and for PSO was 4.3. In CrD patients, when a parent was diagnosed with UC, the SIR for CrD in offspring was 2.4, for AS was 1.8 and for PSO was 1.4. When singleton siblings had UC, the SIR was 2.8 and for AS was 2.1. When a parent and a sibling had UC, the SIR for CD was 5.0 and for RA was 2.2. In twins, the SIR for CrD-UC pairs was 4.9 \[[@B63]\].

Vitiligo
--------

For VIT, three studies assessed familial autoimmunity. The studies done by Alkhateeb *et al*. \[[@B64]\] and Laberge *et al*. \[[@B65]\] discovered a significant increase in the occurrence of three ADs other than VIT, namely, AITD, PA and AdD. Alkhateeb *et al*. also reported the occurrence of SLE, myasthenia gravis (MG) and SSc \[[@B64]\], while Laberge *et al*. found the presence of PSO and RA \[[@B65]\]. In Chinese patients, Zhang *et al*. \[[@B66]\] found a significant association with RA, AA and PSO.

Juvenile rheumatoid arthritis
-----------------------------

Two studies were found on familial autoimmunity in JRA \[[@B67],[@B68]\]. Prahalad *et al*. \[[@B67]\] found that AITD accounted for the familial autoimmunity seen in these probands. Huang *et al*. \[[@B68]\] found, in addition to AITD, the presence of PSO, AS and SLE. Furthermore, Huang *et al*. \[[@B68]\] compared the prevalence of ADs in family members of probands with JRA against the prevalence in family members of probands with JSLE. Including all family members (that is, first, second and third degree relatives), JSLE probands had a greater prevalence of familial autoimmunity than probands with JRA. Nonetheless, in FDR the prevalence of ADs was not significantly different between these two diseases. Thus, familial autoimmunity is equally present in JRA and JSLE. Likewise, Pachman *et al*. \[[@B89]\] compared JRA to JDM and to healthy controls. The only statistically significant association was an increased frequency of RA and PA in FDR of JRA probands.

Juvenile systemic lupus erythematosus
-------------------------------------

Two articles were found for this disease. While Huang *et al*. \[[@B68]\] found that 17% of the FDRs of JSLE probands were affected with an AD, Walters *et al*. \[[@B69]\] found a prevalence of 51%, with 35% of FDRs from JSLE probands having SLE, 30% AITD and 13% PSO.

Idiopathic inflammatory myositis
--------------------------------

Familial autoimmunity has also been assessed for IIM in two studies. The study by Ginn *et al*. \[[@B70]\] found that the most common disease was, once again, AITD followed by RA, T1D and PSO. In this article, OR for familial aggregation of ADs was calculated irrespective of disease status (that is, case or control). The strongest predictors were a blood relative and female gender. Niewold *et al*. \[[@B71]\] reported that FDRs of probands with JDM had a higher frequency of T1D or SLE than in FDRs of controls. However, this relationship did not reach statistical significance.

Celiac disease
--------------

Three articles were found. Petaros et al. \[[@B72]\] found that the prevalence of familial autoimmunity was 4.9% among first and second degree relatives. The ADs that became manifest were AITD, PSO and T1D. In line with these results, Cataldo *et al*. \[[@B73]\] found an increased prevalence of ADs including AITD and T1D. Neuhausen *et al*. \[[@B74]\] also found a significant association with T1D and JRA. However, contrary to what was expected, they found a decreased prevalence of AITD.

Alopecia areata
---------------

An increased frequency of AITD, VIT, T1D, PSO, and CD was found among FDRs of pediatric patients with AA \[[@B75]\].

Discussion
==========

The results found in this work support aggregation of diverse ADs (that is, familial autoimmunity) and the view of a common origin for ADs (that is, the autoimmune tautology). While polyautoimmunity \[[@B7]-[@B9],[@B90],[@B91]\] and familial autoimmune disease \[[@B1],[@B9],[@B42],[@B92]-[@B94]\] are well-supported concepts in the medical literature, few articles have familial autoimmunity as their primary concern. Familial autoimmunity is still a topic that has not been thoroughly explored. To our knowledge, this is the first study specifically designed as a systematic review and meta-analysis to find evidence for familial autoimmunity in five major ADs. Familial autoimmunity uses the concept of \'autoimmune disease\' as a trait that encompasses all pathologies showing evidence of an autoimmune origin. AITD followed by SLE and RA were the most frequent ADs encountered (Figure [8](#F8){ref-type="fig"}).

![**Familial autoimmunity**. The vertical axis corresponds to the proband\'s disease and each disease individually. In the horizontal axis diseases present in first degree relatives are shown. Each color belongs to the proband\'s disease. The figure only includes significant results and may serve as a guide for clinical practice in order to search ADs in FDRs of probands. Note that familial autoimmune disease is excluded. AA, alopecia areata; AdD, Addison\'s disease; AS, ankylosing spondylitis; AITD, autoimmune thyroid disease; CD, celiac disease; CrD, Crohn\'s disease; FDR, first degree relative; IBD, inflammatory bowel disease; IIM, idiopathic inflammatory myositis; JDM, juvenile dermatomyositis; JRA, juvenile rheumatoid arthritis; JSLE, juvenile systemic lupus erythematosus; MAS, multiple autoimmune syndrome; MG, myasthenia gravis; MS, multiple sclerosis; PA, pernicious anemia; PAN, polyarteritis nodosa; PBC, primary biliary cirrhosis; PSO, psoriasis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjögren\'s syndrome; SSc, systemic sclerosis; T1D, type 1 diabetes; UC, ulcerative colitis; VIT, vitiligo; WG, Wegener\'s granulomatosis. Note: Although AS is considered an auto inflammatory more than autoimmune disease \[[@B76]\] we show the results obtained.](1741-7015-11-73-8){#F8}

Our meta-analysis was developed in two stages. First, we wanted to determine the presence of familial autoimmunity as a trait in probands with the five index diseases mentioned earlier. However, a meta-analysis of studies having probands with SLE was not feasible. For the other four index diseases the meta-analyses indicate an increased risk of familial autoimmunity with RRs of 2.4, 1.6, 1.5, and 1.3 for AITD, T1D, RA and MS, respectively. It is not surprising to have AITD as the disease with a greater risk for familial autoimmunity as it is the most common AD worldwide. Meta-analyses with ORs as a measure of association were also done showing a significant relationship of familial autoimmunity with RA and MS probands.

Conversely, for our second approach, instead of grouping the studies for the meta-analyses by the proband\'s disease, we grouped the studies according to the disease present in FDRs. We must look at familial autoimmunity as a two way relationship depending upon which member of the nuclear family is the proband. Accordingly, we developed our second approach which also disclosed the presence of familial autoimmunity in a variety of ADs (Figure [4](#F4){ref-type="fig"} and Additional file [1](#S1){ref-type="supplementary-material"}).

Several reasons may account for the heterogeneity found in our study, which have been also acknowledged by other authors \[[@B90],[@B95]\], namely, different study designs, geographical differences, lack of adequate controls, use of a selected group of probands, and information bias, that is, recall bias \[[@B96]\], diverse population characteristics, and assorted study dates. The quality of studies was certainly influenced by the lack of awareness of familial autoimmunity. In addition, with time diagnostic approaches may have a better performance which may lead to a false increase in diagnoses frequencies.

Aggregation analyses disclosed extreme values (Table [3](#T3){ref-type="table"} and Table [4](#T4){ref-type="table"}), with familial recurrence risk values over 100 as in the case of SSc (λ for SSc in FDRs of SLE probands = 500 to 595) or the case for SLE (λ for SLE in FDRs of MS probands = 471). In addition to these extreme values, we had conflicting results as in the case between MS and RA, and T1D and AITD for which some studies found a lack of aggregation whereas others found the opposite. These discrepancies may be explained by the fact that there are differences in prevalence according to geographical location, that aggregation involves genetic and environmental factors and, also, by the arbitrary calculation of means whenever a prevalence range was reported.

In the clinical setting, clinicians should be aware of familial autoimmunity whenever they are attending patients with ADs (Figure [8](#F8){ref-type="fig"}). A search for autoimmunity in their FDRs should be encouraged by exploring the presence of auto-antibodies \[[@B5]\] and other risk factors \[[@B20],[@B21]\]. Since healthy subjects may have positive autoantibody titers, we decided only to include studies that were based on clinical diseases and not on the presence of autoantibodies.

ADs follow a multifactorial (or complex) inheritance pattern which represents an interaction between the collective effect of the genotype at multiple loci (polygenic or multigenic effects) either to raise or to lower susceptibility to disease, combined with a variety of environmental exposures that may trigger, accelerate, exacerbate, or protect against the disease process. Besides assessing the increased frequency of familial autoimmunity, the search also retrieved studies describing how this familial autoimmunity presents. A predominant inheritance of the autoimmunity trait from mothers was evident in some ADs including SS \[[@B62]\], juvenile idiopathic arthritis \[[@B97]\] and T1D \[[@B40]\]. This is indicative of a preferential transmission of susceptibility alleles from mothers to offspring. Maternal transmission of autoimmunity could be influenced by the high preponderance of ADs in women as compared with the general population. However, this higher than expected frequency of maternal transmission of the autoimmunity trait would warrant further studies of mitochondrial DNA, genomic imprinting, maternal-offspring compatibility, gene-environment and indirect genetic effects in ADs \[[@B62]\].

Another factor that influences familial autoimmunity is race \[[@B40],[@B98],[@B99]\]. Houghton *et al*. \[[@B98]\] compared the prevalence of familial autoimmunity between \'native\' (Amerindian) and other groups in pediatric patients in the United States. In a small sample (6 Amerindians with SLE versus 34 non Amerindian population with SLE ), 83% of the native probands had a familial history of ADs while this was true for only 19% of the non-natives \[[@B98]\]. Meanwhile, with a larger sample size, the GLADEL study found that mestizos had more familial autoimmunity than other racial groups \[[@B42]\]. In fact, ancestry influences the risk and outcome of autoimmunity \[[@B99]\].

We would like to acknowledge the limitations of our study. First, the search was focused on five principal ADs, but we identified articles with probands from other ADs. It is probable that the number of articles retrieved from these ADs is less than if a specific search was done for each of these diseases. Second, we recall the heterogeneity of the study \[[@B100],[@B101]\]. Third, in our search we found articles that did not distinguish between the presence of autoantibodies and a clinical diagnosis of an AD. This also should be taken into account in future studies as the presence of autoantibodies may occur in healthy people. Nevertheless, as stated earlier, they may herald a later onset of a given AD and, therefore, it may be clinically important to follow up those individuals.

Conclusions
===========

The importance of familial autoimmunity has been shown \[[@B102]\]. AITD followed by SLE and RA are the most frequent ADs in familial autoimmunity. Although non-genetic factors may have an effect on familial aggregation, shared genetic factors, in fact, may be the more likely cause for this aggregation \[[@B9]\]. Genes with larger effects (higher penetrance) are related to Mendelian patterns of inheritance, whereas those with smaller effects (lower penetrance) are related rather to complex traits, such as ADs. Identification of such genes, predisposing and affecting the outcome of ADs, is a major challenge for the near future. Given the clinical and etiologic heterogeneity of ADs, understanding the relationship of genotype to phenotype is an extremely important goal for research aimed at gene identification. Thus, further studies of familial autoimmunity will help in increasing the knowledge about the common mechanisms of autoimmunity. Genomics and other related disciplines will offer the tools to accomplish this task, allowing us to predict and prevent ADs, tailor individual medical decisions, and provide personalized healthcare while facilitating the patients\' participation in their treatment and eventual cure of their disease \[[@B103]\].
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###### Additional file 1

**Forest plots depicting risk ratios for familial autoimmunity in first degree relatives**. The figure shows two different analyses. From top to bottom: Addison\'s disease, autoimmune thyroid disease, ankylosing spondylitis, celiac disease, inflammatory bowel disease, discoid lupus, hemolytic anemia, inflammatory idiopathic myositis, immune thrombocytopenic purpura, localized scleroderma, pernicious anemia, myasthenia gravis, multiple sclerosis, polyarteritis nodosa, primary biliary cirrhosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, Sjögren\'s syndrome, systemic sclerosis, type 1 diabetes, vitiligo, Wegener\'s granulomatosis. The summary effect (random effect model) is depicted as a diamond at the bottom of each analysis. The lateral points of each diamond indicate confidence intervals for this estimate.

###### 

Click here for file

###### Additional file 2

**Funnel plots of the three meta-analyses showing publication bias**. The corresponding funnel plot shows the standard error on the Y axis and the log value for common effect size on the horizontal axis. From top to bottom: OR for Type 1 diabetes in first degree relatives, OR for multiple sclerosis in probands, RR for autoimmune thyroid disease in probands. Visual inspection of funnel plots suggested effect sizes for the mentioned analyses were scattered asymmetrically around a central effect. OR, odds ratio; RR, risk ratio.
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